Pancreatectomy with venous resection and peritoneal patch reconstruction: bridging transplantation and pancreatic surgery to combine the advantages of tangential and segmental resections
{"title":"Pancreatectomy with venous resection and peritoneal patch reconstruction: bridging transplantation and pancreatic surgery to combine the advantages of tangential and segmental resections","authors":"Umberto Cillo , Giampaolo Perri , Domenico Bassi, Riccardo Pellegrini, Nicola Canitano, Simone Serafini, Enrico Gringeri , Giovanni Marchegiani","doi":"10.1016/j.hpb.2025.07.010","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Pancreatectomy with venous resection (PVR) is considered standard practice and accomplished with different techniques.</div></div><div><h3>Methods</h3><div>Patients undergoing PVR with portal (PV) and/or superior mesenteric (SMV) vein resection for PDAC between 2015 and 2024 at a high-volume HPB and Liver Transplant Unit were retrospectively analyzed according to ISGPS types.</div></div><div><h3>Results</h3><div>A total of 104 patients underwent PVR: tangential w/primary closure (Type 1 = 30; 29 %) or peritoneal patch (Type 2 = 30; 29 %), segmental w/primary anastomosis (Type 3 = 31; 30 %) or interposition graft (Type 4 = 13; 12 %). Type 2 was mostly used for low (SMV-to-SMV = 37 %) or extended (PV-to-SMV = 50 %) resections (p < 0.001), with lowest rate of splenic vein sacrifice (7 %; p = 0.001). Major morbidity and hemorrhage (PPH) were similar among different ISGPS types (Type 2 = 27 % and 30 %, respectively), as well as mortality (Type 2 = 3 % at 90 days). Prophylactic dose anticoagulation was used in 73 % of Type 2 patients, with 3 % early (≤30 days) and no late (≤1 year) thrombosis.</div></div><div><h3>Discussion</h3><div>The peritoneal patch offers the advantages of both tangential and segmental resections. It can be used for low or extended infiltrations, preserving venous collaterals without sacrificing radicality, with acceptable morbidity and mortality, and near-zero thrombotic events using prophylactic anticoagulation only.</div></div>","PeriodicalId":13229,"journal":{"name":"Hpb","volume":"27 10","pages":"Pages 1318-1327"},"PeriodicalIF":2.4000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hpb","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1365182X25006689","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Pancreatectomy with venous resection (PVR) is considered standard practice and accomplished with different techniques.
Methods
Patients undergoing PVR with portal (PV) and/or superior mesenteric (SMV) vein resection for PDAC between 2015 and 2024 at a high-volume HPB and Liver Transplant Unit were retrospectively analyzed according to ISGPS types.
Results
A total of 104 patients underwent PVR: tangential w/primary closure (Type 1 = 30; 29 %) or peritoneal patch (Type 2 = 30; 29 %), segmental w/primary anastomosis (Type 3 = 31; 30 %) or interposition graft (Type 4 = 13; 12 %). Type 2 was mostly used for low (SMV-to-SMV = 37 %) or extended (PV-to-SMV = 50 %) resections (p < 0.001), with lowest rate of splenic vein sacrifice (7 %; p = 0.001). Major morbidity and hemorrhage (PPH) were similar among different ISGPS types (Type 2 = 27 % and 30 %, respectively), as well as mortality (Type 2 = 3 % at 90 days). Prophylactic dose anticoagulation was used in 73 % of Type 2 patients, with 3 % early (≤30 days) and no late (≤1 year) thrombosis.
Discussion
The peritoneal patch offers the advantages of both tangential and segmental resections. It can be used for low or extended infiltrations, preserving venous collaterals without sacrificing radicality, with acceptable morbidity and mortality, and near-zero thrombotic events using prophylactic anticoagulation only.
期刊介绍:
HPB is an international forum for clinical, scientific and educational communication.
Twelve issues a year bring the reader leading articles, expert reviews, original articles, images, editorials, and reader correspondence encompassing all aspects of benign and malignant hepatobiliary disease and its management. HPB features relevant aspects of clinical and translational research and practice.
Specific areas of interest include HPB diseases encountered globally by clinical practitioners in this specialist field of gastrointestinal surgery. The journal addresses the challenges faced in the management of cancer involving the liver, biliary system and pancreas. While surgical oncology represents a large part of HPB practice, submission of manuscripts relating to liver and pancreas transplantation, the treatment of benign conditions such as acute and chronic pancreatitis, and those relating to hepatobiliary infection and inflammation are also welcomed. There will be a focus on developing a multidisciplinary approach to diagnosis and treatment with endoscopic and laparoscopic approaches, radiological interventions and surgical techniques being strongly represented. HPB welcomes submission of manuscripts in all these areas and in scientific focused research that has clear clinical relevance to HPB surgical practice.
HPB aims to help its readers - surgeons, physicians, radiologists and basic scientists - to develop their knowledge and practice. HPB will be of interest to specialists involved in the management of hepatobiliary and pancreatic disease however will also inform those working in related fields.
Abstracted and Indexed in:
MEDLINE®
EMBASE
PubMed
Science Citation Index Expanded
Academic Search (EBSCO)
HPB is owned by the International Hepato-Pancreato-Biliary Association (IHPBA) and is also the official Journal of the American Hepato-Pancreato-Biliary Association (AHPBA), the Asian-Pacific Hepato Pancreatic Biliary Association (A-PHPBA) and the European-African Hepato-Pancreatic Biliary Association (E-AHPBA).